Drug discovery stands at the heart of developing new therapies; that is the engine behind the medical science in developing new and healthy approaches to save life. As such, the pharmaceutical industry needed rapid responses during the COVID-19 pandemic, so AI was called for finding potential drug candidates. The pharmaceutical industry changes in crises since AI lowers the time and the cost significantly in discovering drugs. Vast data, whether big or small, are efficiently analyzed and processed by AI so that drug candidates are optimized, and drug-target interactions can be predicted, thus shortening the timeline of discovering new treatments.

Rapid advancement of AI technology in drug discovery presents significant challenges for regulatory bodies to maintain safety and efficacy profiles of new treatments. And despite AI's great stride, it still has obstacles in the field. Data integrity and regulatory frameworks are important, as well as the ethical concerns associated with them. The trend of essential integration of AI into drug discovery is sure to emerge given the current evolution of technology, providing the potential for more personalized and effective treatments that can address both current and future health care demands.